Q4 2024 Eli Lilly and Co Earnings Call Transcript
Key Points
- Eli Lilly and Co (LLY) reported a 32% increase in full-year revenue for 2024, exceeding guidance by $4 billion.
- The company achieved a 45% revenue growth in Q4 2024, driven by strong performance of new products like Mounjaro and Zepbound.
- Eli Lilly and Co (LLY) advanced its pipeline with positive Phase 3 results for several drugs and initiated new Phase 3 programs.
- The company expanded its manufacturing capacity with significant investments in Indiana, Wisconsin, and Ireland.
- Eli Lilly and Co (LLY) returned $3 billion to shareholders through dividends and share repurchases, and announced a $15 billion share repurchase program.
- R&D expenses increased by 18% due to continued investment in early and late-stage portfolios.
- Marketing, selling, and administrative expenses rose by 26%, driven by promotional efforts for new and future launches.
- The effective tax rate increased to 13.2%, impacting overall profitability.
- Realized prices in the US decreased by 5% due to changes in rebates and discounts.
- There are concerns about the sustainability of operating margin expansions, with some questioning if the manufacturing buildout may be too aggressive.
Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q4 2024 earnings call. (Operator Instructions)
I would now like to turn the conference over to your host, Mike Czapar, Senior Vice President of Investor Relations. Mike, please go ahead.
Good morning. Thank you for joining us for Eli Lilly and Company's Q4 2024 earnings call. I'm Mike Czapar, Senior Vice President of Investor Relations.
Joining me on today's call are Dave Ricks, Lilly's Chair and CEO; Dr. Dan Skovronsky, Chief Scientific Officer and President of Lilly Immunology; Lucas Montarce, Chief Financial Officer; Anne White, President of Lilly Neuroscience; Ilya Yuffa, President of Lilly International; Jake Van Naarden, President of Lilly Oncology; and Patrik Jonsson, President of Lilly Cardiometabolic Health and Lilly USA. We're also joined by Mart Keenan, Wes Taul, and Wai Wong of the investor relations team.
During the call, we anticipate making projections and forward-looking
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
